Clinical characteristics of the eyes at baseline
| Gender | BCVA (decimal) | FST blue (0 dB=0.01 cd/m2) | FST red (0 dB=0.01 cd/m2) | |
| P1 RE | Female | 0.125 | −0.83 dB | 1.5 dB |
| P1 LE | Female | 0.16 | −9.71 dB | −1.93 dB |
| P2 LE | Female | 0.025 | 0.22 dB | 3.7 dB |
| P3 LE | Female | 0.06 | −0.72 dB | 2.73 dB |
| P4 RE | Female | FC | −4.15 dB | 0.85 dB |
| P4 LE | Female | FC | −0.91 dB | 3.18 dB |
| P8 LE | Male | 0.2 | −7.6 dB | −4.21 dB |
Seven eyes of five patients with retinal dystrophy caused by bi-allelic RPE65 mutations have been treated with voretigene neparvovec. In all patients, there was no measurable rod function before the treatment and reduced visual acuity.
BCVA, best corrected visual acuity; FC, finger counting; FST, full-field stimulus threshold; LE, left eye; RE, right eye.